Laxxon Medical GmbH

Using their SPID®-Technology, Laxxon Medical has manufactured a 3D printed oral tablet combining a GLP-1 receptor agonist and a permeation enhancer intended to increase bioavailability LXM.2 is being developed using the 505(b)2 pathway with an expected NDA submission in early 2027 Laxxon is seeking to partner or out-license LXM.2 NEW YORK, NY / ACCESSWIRE / May 22, 2024 / Laxxon Medical announced today the development program for LXM.2, a 3D printed oral glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of adults and pediatric patients 12 years and older with obesity. LXM.2 is an enterically coated oral solid tablet consisting of a GLP-1 receptor agonist combined with a permeation enhancer intended to increase bioavailability. The addition of the permeation enhancer was made possible using Laxxon Medical's SPID® (Screen Printed Innovative Drug) platform technology. "Polypeptides and proteins like GLP-1s are known to have low bioavailability due to the degradation in the GI tract and poor uptake, meaning they need protection from degradation and their absorption benefits from permeation enhancers. Traditionally, it has been difficult to manufacture products containing the permeation enhancer via conventional methods, such as direct compression or granulation, given its physicochemical properties. It has additionally been challenging for these traditional manufacturing methods to apply an enteric coating to the finished product." said Dr. Achim Schneeberger, Laxxon Medical's Chief Scientific Officer. "SPID®-Technology is not only characterized by precise and tailored dosing - its unique formulation allows manufacturing of oral solids containing clinically relevant doses of permeation enhancers at convincing hardness and low friability." The active pharmaceutical ingredient (API) in LXM.2 has already been approved by the FDA for use in adults and pediatric patients 12 years and older with obesity. LXM.2 is eligible to be developed using the 505(b)2 pathway. Laxxon has designed a streamlined development program and is targeting an NDA submission in early 2027. Laxxon Medical CEO Helmut Kerschbaumer said: "LXM.2 would be a game-changer for patients struggling with obesity. Injectable medications, while effective, can be inconvenient and pose a barrier for some people. An oral option would offer greater ease of use and potentially improve adherence to treatment. This could significantly increase the number of patients who can successfully manage their weight and achieve long-term health benefits. The ability to use the 505(b)2 pathway means we can potentially get LXM.2 to patients quickly." Laxxon is seeking to partner or out-license LXM.2. A team of Laxxon Medical representatives will be attending BIO in San Diego, June 3-8, 2024. Read more about LXM.2 here. About Laxxon Medical Laxxon Medical is a pharma-technology company pioneering a new generation of advanced pharmaceuticals with SPID®, a novel 3D screen printing platform technology. For new and common pharmaceutical drugs, SPID® unlocks innovative drug delivery advancements paired with fast-tracked market access and extensive IP protection to yield disruptive opportunities for partners and life-changing results for patients. Laxxon's pipeline includes ongoing working-projects with notable pharma players, biotech companies and research universities, in addition to 13 in-house Advanced Patented Generics products. Laxxon's IP is continuously growing and consists of 150 patents and patent applications with more than 3,000 patent claims. Investor Contact: Alexander Ruckdaeschel, Chief Strategy Directoralexander.ruckdaeschel@laxxonmedical.com Business Development Contact: Jessica McHargue, Director of Business Development jessica.mchargue@laxxonmedical.com Media Contact: Frances Hoggard, Communications Manager frances.hoggard@laxxonmedical.com SOURCE: Laxxon Medical View the original press release on accesswire.com

NEW YORK, NY / ACCESSWIRE / December 18, 2023 / Laxxon Medical, a leading pharma-technology company pioneering a new generation of advanced pharmaceuticals, today announced that management is scheduled to participate in the 26th Annual Needham Growth Conference on January 17th and 18th, 2024 in New York City. Laxxon CEO/Chairman Helmut Kerschbaumer and Chief Strategy Officer Alexander Ruckdaeschel will participate in one-on-one meetings with institutional, private equity, and venture capital investors. The conference will be held onsite at the Lotte New York Palace in New York City on Wednesday, January 17th, and Thursday, January 18th, with virtual access on Tuesday, January 16th, and Friday, January 19th. For more information about the conference or to schedule a one-on-one meeting with Laxxon Medical, please get in touch with your Needham representative. About Laxxon Medical Laxxon Medical is a pharma-technology company pioneering a new generation of advanced pharmaceuticals with SPID®, a novel 3D screen printing platform technology. For new and common pharmaceutical drugs, SPID® unlocks innovative drug delivery advancements paired with fast-tracked market access and extensive IP protection to yield disruptive opportunities for partners and life-changing results for patients. Laxxon's pipeline includes ongoing working-projects with notable pharma players, biotech companies and research universities, in addition to 13 in-house Advanced Patented Generics products. Laxxon's IP is continuously growing and consists of 150 patents and patent applications with more than 3,000 patent claims. Laxxon is partnered with CDMO Hovione and is jointly establishing cGMP productions in Portugal and the United States. Company website: . Investor Contact: Alexander Ruckdaeschel Chief Strategy Director a.ruckdaeschel@laxxonmedical.com Media Contact: Frances Hoggard Communications Manager f.hoggard@laxxonmedical.com SOURCE: Laxxon Medical View the original press release on accesswire.com

NEW YORK, NY / ACCESSWIRE / December 6, 2023 / Laxxon Medical announced today its attendance at the 42nd Annual J.P. Morgan Healthcare Conference, taking place January 8-11, 2024, in San Francisco, California. The J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, connecting global industry leaders, emerging fast-growth companies and innovative technologies of the investment community. Representing Laxxon Medical at the J.P.Morgan Healthcare Conference is CEO Helmut Kerschbaumer and Chief Strategy Officer Alexander Ruckdaeschel, who will meet with institutional investors. About Laxxon Medical Laxxon Medical is a pharma-technology company pioneering a new generation of advanced pharmaceuticals with SPID®, a novel 3D screen printing platform technology. For new and common pharmaceutical drugs, SPID® unlocks innovative drug delivery advancements paired with fast-tracked market access and extensive IP protection to yield disruptive opportunities for partners and life-changing results for patients. Laxxon's pipeline includes ongoing working-projects with notable pharma players, biotech companies and research universities, in addition to 13 in-house Advanced Patented Generics products. Laxxon's IP is continuously growing and consists of 150 patents and patent applications with more than 3,000 patent claims. Laxxon is partnered with CDMO Hovione and is jointly establishing cGMP productions in Portugal and the United States. Company website: . Company Contact Frances Hoggard | Communications Manager | f.hoggard@laxxonmedical.com SOURCE: Laxxon Medical View source version on accesswire.com: